Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lipoproteins | 6 | 2023 | 876 | 1.710 |
Why?
|
Triglycerides | 7 | 2023 | 2450 | 1.690 |
Why?
|
Peripheral Arterial Disease | 7 | 2023 | 1184 | 1.400 |
Why?
|
Cardiovascular Diseases | 24 | 2023 | 15108 | 1.130 |
Why?
|
C-Reactive Protein | 18 | 2023 | 3766 | 1.050 |
Why?
|
Diabetes Mellitus, Type 2 | 24 | 2020 | 11695 | 0.980 |
Why?
|
Cholesterol, LDL | 6 | 2020 | 2354 | 0.900 |
Why?
|
Hyperhomocysteinemia | 1 | 2021 | 124 | 0.750 |
Why?
|
Ankle Brachial Index | 1 | 2020 | 154 | 0.700 |
Why?
|
Natriuretic Peptide, Brain | 4 | 2017 | 1573 | 0.700 |
Why?
|
Peripheral Vascular Diseases | 3 | 2009 | 550 | 0.690 |
Why?
|
Hypertriglyceridemia | 2 | 2021 | 293 | 0.690 |
Why?
|
Homocysteine | 3 | 2021 | 647 | 0.670 |
Why?
|
Intercellular Adhesion Molecule-1 | 6 | 2020 | 1155 | 0.650 |
Why?
|
Benzoxazoles | 1 | 2018 | 78 | 0.620 |
Why?
|
Butyrates | 1 | 2018 | 163 | 0.620 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2018 | 179 | 0.580 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 255 | 0.550 |
Why?
|
Peptide Fragments | 4 | 2017 | 5095 | 0.510 |
Why?
|
Hypolipidemic Agents | 1 | 2019 | 604 | 0.480 |
Why?
|
Troponin T | 3 | 2017 | 749 | 0.480 |
Why?
|
Inflammation | 10 | 2023 | 10578 | 0.470 |
Why?
|
Incidence | 19 | 2021 | 20928 | 0.460 |
Why?
|
Atherosclerosis | 5 | 2023 | 3428 | 0.450 |
Why?
|
Anti-Inflammatory Agents | 3 | 2018 | 1788 | 0.450 |
Why?
|
Cholesterol | 2 | 2023 | 2895 | 0.410 |
Why?
|
Venous Thromboembolism | 3 | 2021 | 1668 | 0.410 |
Why?
|
Anticholesteremic Agents | 2 | 2018 | 979 | 0.410 |
Why?
|
Interleukin-6 | 8 | 2018 | 3199 | 0.400 |
Why?
|
Lipoproteins, VLDL | 4 | 2021 | 201 | 0.400 |
Why?
|
Hyperinsulinism | 2 | 2006 | 415 | 0.390 |
Why?
|
Eicosapentaenoic Acid | 1 | 2015 | 582 | 0.380 |
Why?
|
Dyslipidemias | 1 | 2018 | 848 | 0.380 |
Why?
|
Adiponectin | 2 | 2019 | 1099 | 0.380 |
Why?
|
Coronary Artery Disease | 6 | 2023 | 6454 | 0.370 |
Why?
|
Prospective Studies | 27 | 2023 | 53187 | 0.350 |
Why?
|
Risk Assessment | 18 | 2022 | 23320 | 0.340 |
Why?
|
Risk Factors | 36 | 2023 | 72145 | 0.340 |
Why?
|
Diabetes Complications | 4 | 2011 | 1359 | 0.340 |
Why?
|
Docosahexaenoic Acids | 1 | 2015 | 875 | 0.320 |
Why?
|
Metformin | 2 | 2017 | 829 | 0.310 |
Why?
|
Insulin | 4 | 2009 | 6575 | 0.310 |
Why?
|
Hypoglycemic Agents | 3 | 2017 | 2866 | 0.300 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 9941 | 0.300 |
Why?
|
Middle Aged | 52 | 2021 | 213127 | 0.290 |
Why?
|
Methotrexate | 3 | 2020 | 1720 | 0.280 |
Why?
|
Coronary Disease | 5 | 2005 | 6078 | 0.280 |
Why?
|
Aspirin | 4 | 2015 | 3278 | 0.260 |
Why?
|
Lipoprotein(a) | 3 | 2022 | 425 | 0.250 |
Why?
|
Vitamin E | 3 | 2015 | 869 | 0.250 |
Why?
|
Female | 57 | 2021 | 379592 | 0.240 |
Why?
|
Arteriosclerosis | 3 | 2004 | 1092 | 0.240 |
Why?
|
Women's Health | 5 | 2015 | 2034 | 0.240 |
Why?
|
Humans | 74 | 2023 | 742088 | 0.220 |
Why?
|
Case-Control Studies | 13 | 2021 | 21719 | 0.220 |
Why?
|
Proinsulin | 1 | 2003 | 133 | 0.220 |
Why?
|
Sex Factors | 7 | 2021 | 10392 | 0.210 |
Why?
|
Obesity | 6 | 2019 | 12705 | 0.210 |
Why?
|
Dietary Supplements | 1 | 2015 | 3294 | 0.210 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2004 | 425 | 0.210 |
Why?
|
Apolipoproteins | 2 | 2021 | 315 | 0.210 |
Why?
|
Medicare | 1 | 2020 | 6532 | 0.210 |
Why?
|
Interleukin-1beta | 3 | 2018 | 972 | 0.200 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 2043 | 0.200 |
Why?
|
Chylomicron Remnants | 1 | 2021 | 3 | 0.200 |
Why?
|
Vitamin D | 1 | 2015 | 3211 | 0.200 |
Why?
|
Cholesterol, HDL | 4 | 2020 | 1813 | 0.200 |
Why?
|
Fibric Acids | 1 | 2021 | 25 | 0.190 |
Why?
|
Postmenopause | 3 | 2006 | 2461 | 0.190 |
Why?
|
Cohort Studies | 11 | 2020 | 40450 | 0.190 |
Why?
|
Double-Blind Method | 9 | 2020 | 12017 | 0.190 |
Why?
|
Blood Glucose | 6 | 2018 | 6249 | 0.180 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39004 | 0.180 |
Why?
|
Colchicine | 1 | 2021 | 242 | 0.180 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 12344 | 0.180 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 707 | 0.180 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1202 | 0.170 |
Why?
|
Lipoproteins, HDL | 3 | 2020 | 637 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3239 | 0.170 |
Why?
|
Time Factors | 6 | 2021 | 40054 | 0.170 |
Why?
|
Smoking | 4 | 2015 | 8969 | 0.170 |
Why?
|
Tissue Plasminogen Activator | 2 | 2005 | 1262 | 0.160 |
Why?
|
Aged | 29 | 2022 | 162944 | 0.160 |
Why?
|
Insulin Resistance | 6 | 2020 | 3861 | 0.160 |
Why?
|
Drug Therapy, Combination | 5 | 2018 | 6483 | 0.160 |
Why?
|
United States | 14 | 2021 | 69693 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2023 | 786 | 0.160 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1780 | 0.150 |
Why?
|
Body Mass Index | 11 | 2020 | 12695 | 0.150 |
Why?
|
Calgranulin B | 2 | 2007 | 84 | 0.140 |
Why?
|
Blood Pressure | 2 | 2011 | 8541 | 0.140 |
Why?
|
Adipose Tissue | 4 | 2019 | 3278 | 0.140 |
Why?
|
Cerebrovascular Disorders | 1 | 2023 | 1499 | 0.140 |
Why?
|
Leptin | 2 | 2016 | 1593 | 0.130 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2018 | 507 | 0.130 |
Why?
|
Diabetes Mellitus | 4 | 2016 | 5724 | 0.130 |
Why?
|
Secondary Prevention | 1 | 2021 | 1520 | 0.120 |
Why?
|
Hypertension | 2 | 2011 | 8455 | 0.120 |
Why?
|
Diet, Mediterranean | 1 | 2020 | 696 | 0.120 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 262 | 0.120 |
Why?
|
Predictive Value of Tests | 6 | 2015 | 15056 | 0.120 |
Why?
|
Fasting | 3 | 2006 | 1589 | 0.120 |
Why?
|
Myocardial Infarction | 6 | 2018 | 11690 | 0.110 |
Why?
|
Lower Extremity | 1 | 2021 | 1151 | 0.110 |
Why?
|
Male | 27 | 2022 | 349538 | 0.110 |
Why?
|
Molecular Weight | 2 | 2011 | 2255 | 0.100 |
Why?
|
Risk | 3 | 2013 | 9679 | 0.100 |
Why?
|
Research Report | 1 | 2015 | 355 | 0.100 |
Why?
|
Heart Atria | 2 | 2008 | 1348 | 0.100 |
Why?
|
Atrial Natriuretic Factor | 1 | 2013 | 393 | 0.100 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2021 | 1341 | 0.100 |
Why?
|
Lipids | 3 | 2019 | 3302 | 0.100 |
Why?
|
Statistics, Nonparametric | 3 | 2018 | 2885 | 0.100 |
Why?
|
Disease Management | 2 | 2020 | 2450 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15494 | 0.090 |
Why?
|
Fluorobenzenes | 1 | 2012 | 184 | 0.090 |
Why?
|
Age Factors | 5 | 2021 | 18355 | 0.090 |
Why?
|
Placebos | 2 | 2020 | 1677 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1335 | 0.090 |
Why?
|
Drug Combinations | 1 | 2015 | 1961 | 0.090 |
Why?
|
Insulin, Long-Acting | 1 | 2009 | 57 | 0.090 |
Why?
|
Body Weight | 4 | 2014 | 4664 | 0.090 |
Why?
|
Systole | 1 | 2011 | 956 | 0.080 |
Why?
|
Diastole | 1 | 2011 | 791 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 7901 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2495 | 0.080 |
Why?
|
Immunoassay | 1 | 2012 | 752 | 0.080 |
Why?
|
Polysaccharides | 1 | 2015 | 1051 | 0.080 |
Why?
|
Estrogen Receptor beta | 1 | 2009 | 175 | 0.080 |
Why?
|
Death, Sudden, Cardiac | 1 | 2016 | 1541 | 0.080 |
Why?
|
Life Style | 3 | 2014 | 3824 | 0.080 |
Why?
|
Calgranulin A | 1 | 2007 | 79 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 357 | 0.070 |
Why?
|
Antioxidants | 1 | 2015 | 1659 | 0.070 |
Why?
|
Neoplasms | 2 | 2015 | 21596 | 0.070 |
Why?
|
Forms and Records Control | 1 | 2007 | 160 | 0.070 |
Why?
|
Echocardiography, Doppler | 2 | 2008 | 934 | 0.070 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 3510 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2012 | 4414 | 0.070 |
Why?
|
Prognosis | 3 | 2021 | 29010 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2015 | 3067 | 0.070 |
Why?
|
Heptanoic Acids | 1 | 2007 | 343 | 0.070 |
Why?
|
Anthropometry | 2 | 2008 | 1350 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4147 | 0.070 |
Why?
|
Pravastatin | 1 | 2007 | 395 | 0.070 |
Why?
|
Cardiotonic Agents | 1 | 2008 | 535 | 0.060 |
Why?
|
Statistics as Topic | 1 | 2011 | 2372 | 0.060 |
Why?
|
Body Size | 1 | 2008 | 461 | 0.060 |
Why?
|
Estrogen Receptor alpha | 1 | 2009 | 577 | 0.060 |
Why?
|
Logistic Models | 5 | 2016 | 13403 | 0.060 |
Why?
|
Atrial Fibrillation | 2 | 2014 | 5019 | 0.060 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 517 | 0.060 |
Why?
|
Fibrinogen | 1 | 2008 | 894 | 0.060 |
Why?
|
Odds Ratio | 4 | 2007 | 9846 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2012 | 3199 | 0.060 |
Why?
|
Confidence Intervals | 3 | 2018 | 2970 | 0.060 |
Why?
|
Reference Values | 4 | 2016 | 4982 | 0.060 |
Why?
|
Lipoproteins, LDL | 2 | 2020 | 628 | 0.060 |
Why?
|
Carotenoids | 1 | 2006 | 624 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2021 | 62966 | 0.060 |
Why?
|
Sulfonamides | 1 | 2012 | 1932 | 0.050 |
Why?
|
Patient Selection | 1 | 2015 | 4214 | 0.050 |
Why?
|
Social Class | 1 | 2011 | 1995 | 0.050 |
Why?
|
Diet | 3 | 2020 | 7923 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 17400 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2011 | 6365 | 0.050 |
Why?
|
Creatinine | 1 | 2008 | 1916 | 0.050 |
Why?
|
Endocarditis, Bacterial | 1 | 2006 | 453 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2007 | 820 | 0.050 |
Why?
|
Lovastatin | 1 | 2002 | 120 | 0.050 |
Why?
|
Genome-Wide Association Study | 2 | 2021 | 12220 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2008 | 12242 | 0.050 |
Why?
|
Pyrroles | 1 | 2007 | 1143 | 0.050 |
Why?
|
Primary Prevention | 1 | 2008 | 1166 | 0.050 |
Why?
|
Adult | 11 | 2021 | 213712 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.050 |
Why?
|
Comorbidity | 2 | 2007 | 10372 | 0.050 |
Why?
|
Solubility | 1 | 2002 | 1083 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10232 | 0.050 |
Why?
|
Pyrimidines | 1 | 2012 | 2933 | 0.050 |
Why?
|
Apolipoprotein B-100 | 1 | 2020 | 148 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2019 | 57683 | 0.050 |
Why?
|
Migraine Disorders | 1 | 2012 | 1620 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 3760 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2015 | 13921 | 0.040 |
Why?
|
Apolipoprotein A-I | 1 | 2020 | 280 | 0.040 |
Why?
|
Premedication | 1 | 2020 | 257 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 12071 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2011 | 2068 | 0.040 |
Why?
|
Antigens | 1 | 2004 | 1462 | 0.040 |
Why?
|
Glucose Intolerance | 1 | 2002 | 577 | 0.040 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2020 | 249 | 0.040 |
Why?
|
Quantitative Trait, Heritable | 1 | 2021 | 544 | 0.040 |
Why?
|
Transaminases | 1 | 2018 | 199 | 0.040 |
Why?
|
Patient Compliance | 1 | 2008 | 2680 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9410 | 0.040 |
Why?
|
Abdomen | 1 | 2003 | 1107 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2003 | 744 | 0.040 |
Why?
|
Policy | 1 | 2021 | 504 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2016 | 13029 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2003 | 1351 | 0.040 |
Why?
|
American Heart Association | 1 | 2021 | 1055 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14720 | 0.030 |
Why?
|
Weight Gain | 1 | 2006 | 2282 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 764 | 0.030 |
Why?
|
Blood Platelets | 1 | 2006 | 2506 | 0.030 |
Why?
|
Echocardiography | 1 | 2008 | 5097 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2006 | 2059 | 0.030 |
Why?
|
Menopause | 1 | 2003 | 1621 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 291 | 0.030 |
Why?
|
Acute Coronary Syndrome | 1 | 2007 | 2337 | 0.030 |
Why?
|
Regression Analysis | 1 | 2003 | 6452 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2021 | 1887 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 493 | 0.030 |
Why?
|
Probability | 2 | 2008 | 2502 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2006 | 7770 | 0.030 |
Why?
|
Body Height | 2 | 2008 | 1574 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2015 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1655 | 0.020 |
Why?
|
Adiposity | 1 | 2020 | 1806 | 0.020 |
Why?
|
Lipoproteins, IDL | 1 | 2010 | 18 | 0.020 |
Why?
|
Thrombosis | 1 | 2004 | 2966 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2003 | 3957 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6931 | 0.020 |
Why?
|
Inflammation Mediators | 2 | 2011 | 1889 | 0.020 |
Why?
|
Sweetening Agents | 1 | 2012 | 296 | 0.020 |
Why?
|
Exercise | 1 | 2006 | 5611 | 0.020 |
Why?
|
Stroke | 2 | 2018 | 9963 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2005 | 24913 | 0.020 |
Why?
|
Body Surface Area | 1 | 2008 | 198 | 0.020 |
Why?
|
Vitamins | 1 | 2015 | 1608 | 0.020 |
Why?
|
Health Care Costs | 1 | 2020 | 3203 | 0.020 |
Why?
|
Xanthophylls | 1 | 2006 | 96 | 0.020 |
Why?
|
Beverages | 1 | 2012 | 820 | 0.020 |
Why?
|
Lutein | 1 | 2006 | 125 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2005 | 6754 | 0.020 |
Why?
|
Disease Progression | 1 | 2002 | 13256 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10943 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3862 | 0.020 |
Why?
|
beta Carotene | 1 | 2006 | 527 | 0.020 |
Why?
|
Bundle-Branch Block | 1 | 2006 | 270 | 0.020 |
Why?
|
Reference Standards | 1 | 2008 | 1020 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 906 | 0.010 |
Why?
|
Educational Status | 1 | 2011 | 2533 | 0.010 |
Why?
|
Acute Disease | 2 | 2006 | 7141 | 0.010 |
Why?
|
Adolescent | 4 | 2019 | 85649 | 0.010 |
Why?
|
Stroke Volume | 2 | 2006 | 4983 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7276 | 0.010 |
Why?
|
Lectins, C-Type | 1 | 2006 | 588 | 0.010 |
Why?
|
Income | 1 | 2011 | 1904 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8662 | 0.010 |
Why?
|
Myocardium | 1 | 2015 | 4775 | 0.010 |
Why?
|
Haplotypes | 1 | 2009 | 2781 | 0.010 |
Why?
|
Hemostasis | 1 | 2005 | 458 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 692 | 0.010 |
Why?
|
Megakaryocytes | 1 | 2006 | 542 | 0.010 |
Why?
|
International Classification of Diseases | 1 | 2007 | 865 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3587 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16331 | 0.010 |
Why?
|
Random Allocation | 1 | 2006 | 2425 | 0.010 |
Why?
|
Pacemaker, Artificial | 1 | 2006 | 817 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 971 | 0.010 |
Why?
|
Doxorubicin | 1 | 2006 | 2215 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15530 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4751 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 2007 | 2161 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 2006 | 1398 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 5979 | 0.010 |
Why?
|
Antigens, CD | 1 | 2006 | 4024 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15194 | 0.010 |
Why?
|
Mice | 2 | 2016 | 81045 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19862 | 0.010 |
Why?
|
Animals | 3 | 2016 | 168561 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2006 | 3656 | 0.010 |
Why?
|
Survival Rate | 1 | 2007 | 12773 | 0.010 |
Why?
|
Linear Models | 1 | 2003 | 5948 | 0.010 |
Why?
|
Electrocardiography | 1 | 2006 | 6440 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 56350 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 13853 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2006 | 7721 | 0.010 |
Why?
|
Apoptosis | 1 | 2006 | 9715 | 0.010 |
Why?
|
Child | 2 | 2008 | 77478 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2006 | 21821 | 0.000 |
Why?
|
Infant | 1 | 2008 | 35070 | 0.000 |
Why?
|
Child, Preschool | 1 | 2008 | 40955 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2008 | 77098 | 0.000 |
Why?
|